Investors

Print Page Print Page | E-mail Page E-mail Page | RSS Feeds RSS Feeds

Webcast ImageWebcast
AcelRx Pharmaceuticals, Inc. at the BIO CEO & Investor Conference (Replay)
02/09/16 at 1:00 p.m. ET
AcelRx Pharmaceuticals, Inc. at the BIO CEO & Investor Conference
Tuesday, February 9, 2016 1:00 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
PDF File ACRX Corporate Presentation - 9/14/15
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain. AcelRx's lead product candidate, Zalviso, is designed to solve the problems associated with post-operative intravenous patient-controlled analgesia which has been shown to cause harm to patients following surgery because of the side effects of morphine, the invasive IV route of delivery and the complexity of infusion pumps. AcelRx has announced positive results from each of the three Phase 3 clinical trials for Zalviso and has submitted an NDA to the FDA seeking its approval. AcelRx also announced positive top-line results for a Phase 2 trial for ARX-04, a sufentanil formulation for the treatment of moderate-to-severe acute pain, funded through a grant from U.S. Army Medical Research and Materiel Command. The company has two additional pain treatment product candidates, ARX-02 and ARX-03, which have completed Phase 2 clinical development.
ACRX (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$3.47
Change (%) Stock is Up 0.11 (3.27%)
Volume339,792
Data as of 02/09/16 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote

Recent News

    More >>
02/03/16AcelRx Pharmaceuticals to Present at Two Upcoming Investor Events in February
REDWOOD CITY, Calif., Feb. 3, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today announced that Chief Financial Officer and Head of Business Development, Timothy E. Morris will be presenting at the 18th Annual BIO CEO & Investor Conference and the 2016 RBC Capital Markets' Healthcare Conference in New York. Details of the conference... 
Printer Friendly Version
01/21/16AcelRx Pharmaceuticals Announces Presentation of Phase 3 Sufentanil Sublingual 30 mcg Tablet (ARX-04) Data at the European Congress of Ambulatory Surgery
Phase 3 Clinical Data Highlights Safety and Efficacy of Sublingual Sufentanil in Outpatient Abdominal Surgery Populations REDWOOD CITY, Calif., Jan. 21, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) today announced that a presentation will be made at the annual European Congress of Ambulatory Surgery to be held January 28th and 29th, 2016 at the Disneyland Hotel New York Convention Centre in Paris, France.  This bilingual congress (simultaneous translation will be provided)... 
Printer Friendly Version
01/10/16AcelRx Pharmaceuticals Announces Anticipated 2016 Milestones
- ARX-04 ER and Postoperative Study Results, NDA Submission - Initiation and Completion of Final Phase 3 trial in the U.S. for Zalviso, NDA Resubmission - Zalviso™ Commercial Launch in the European Union REDWOOD CITY, Calif., Jan. 10, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today announced anticipated 2016 milestones for i... 
Printer Friendly Version

Upcoming Events

    More >>
DateTitle
03/09/16 10:00 a.m. ET
AcelRx Pharmaceuticals, Inc. at the Cowen and Company 36th Annual Health Care Conference
LocationBoston Marriott Copley Place
Boston, MA

Receive E-mail Alerts 

Sign up to receive e-mail alerts whenever AcelRx Pharmaceuticals, Inc. posts new information to the site. Just enter your e-mail address and click Submit.
 

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

AcelRX

CONTACT